Clinical Trial

Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.
Trial Details
NCT Number NCT07429162
Lead Sponsor Alberta Health services
Conditions Mycobacterium Abscessus Infection, Bacteriophage Therapy, Pulmonary Disease
Enrollment 1 participants
Start Date 2026-07-02
Primary Completion 2027-07-02 (estimated)
Study Completion 2028-07-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-24